TITLE:

Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator.

AUTHOR(S):

Uesugi, Yoshiko; Kawata, Hiroyuki; Saito, Yoshihiko; Tabata, Yasuhiko

CITATION:

Uesugi, Yoshiko ...[et al]. Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator.. Journal of drug targeting 2012, 20(3): 224-234

ISSUE DATE:

2012-04

URL:

<http://hdl.handle.net/2433/174341>

RIGHT:

© 2012 Informa Plc.; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。

Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator

Yoshiko Uesugi^a, Hiroyuki Kawata^b, Yoshihiko Saito^b, and Yasuhiko Tabata^{a,*}

^a *Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan*

^b *First Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan*

*** Corresponding author:** Yasuhiko Tabata

Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Tel.: +81 75 751 4121; Fax: +81 75 751 4646; E-mail: yasuhiko@frontier.kyoto-u.ac.jp

Short title: Ultrasound-responsive t-PA nano complexes

Key words: t-PA, thrombolytic therapy, gelatin, metal ions, ultrasound

ABSTRACT

This study is undertaken to design zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator (t-PA) for thrombolytic therapy where the t-PA activity can be recovered in the blood circulation upon ultrasound irradiation. Various molecular weights of gelatin were complexed with t-PA by their simply mixing in aqueous solution. Then, zinc acetate, calcium acetate or magnesium acetate was added to form nano-sized gelatin–t-PA complexes. The complexes had the apparent molecular size of about 100 nm. When zinc ions were added to the gelatin–t-PA complexes, the t-PA activity was suppressed most strongly to 57% of the original, free t-PA activity. Upon ultrasound exposure *in vitro*, the t-PA activity was fully recovered. A cell culture experiment with L929 fibroblasts demonstrated no cytotoxicity of complexes at the concentration used for the *in vivo* experiment. The half-life of t-PA in the blood circulation prolonged by the complexation with gelatin and zinc ions. The zinc-stabilized t-PA–gelatin complex is a promising t-PA delivery system which can manipulate the thrombolytic activity by the local ultrasound irradiation.

1 INTRODUCTION

2 In acute myocardial infarction, treatment strategies aimed at rapidly restoring complete and
3 persistent coronary flow, and the recanalisation of infarct artery is the target of both
4 pharmacological and mechanical reperfusion techniques. Tissue-type plasminogen activator
5 (t-PA) is widely used as a thrombolytic drug because of its high fibrin specificity (Armstrong &
6 Collen, 2001) and efficacy if administered early. However, t-PA has some adverse effects to be
7 clinically resolved, including the risk of allergic reactions, bleeding complications, and short
8 half-life (Blann et al., 2002; Bode et al., 1996; Turpie et al., 2002), which often limits the
9 therapeutic applications. In fact, among patients treated with plasminogen activators,
10 approximately 20% showed the adverse effect of bleeding (Chung et al., 2008). Therefore, the
11 targeted delivery of thrombolytic drugs only to the necessary site is an attractive strategy to
12 avoid such side effects. Drug delivery system (DDS) is a technology or methodology to
13 efficiently delivery drugs to the site of action by making use of carrier materials. For the
14 thrombolytic applications, several investigations on the delivery of t-PA have been reported
15 (Chung et al., 2008; Tiukinhoy-Laing et al., 2007; Shaw et al., 2009; Heeremans et al., 1995;
16 Smith et al., 2010; Molina et al., 2006; Collis et al., 2010).

17 Recently, an increasing interest has been expressed in intelligent DDS that has the capacity
18 for triggered release by external factors, such as ultrasound, temperature, pH, or
19 electromagnetic fields (Tiukinhoy-Laing et al., 2007; Rapoport et al., 2002; Marin et al., 2001;
20 Daocheng and Mingxi, 2008; Frinking et al., 1998; Huang and MacDonald, 2004). Among
21 these factors, ultrasound is one of the attractive methodologies to control drug release, as it is
22 non-invasive and can deeply penetrate into the interior of body. Several systems of
23 ultrasound-triggered drug release, specifically the poly (DL lactide-co-glycolide) system
24 (Frinking et al., 1998) and acoustically active liposomes (Huang and MacDonald, 2004), have
25 been reported. However, all of the ultrasound triggered release systems cannot be used

clinically because of their low sensitivity in response to ultrasound stimulation and the poor drug loading.

To date, we have explored various DDS carriers of gelatin. Gelatin has been extensively used for industrial, pharmaceutical, and medical applications, and the bio-safety has been proved through the long clinical usages as surgical biomaterials and drug ingredients (Veis, 1965). Biodegradable hydrogels of gelatin and the derivatives have been designed for the controlled release of various drugs, such as basic fibroblast factor (bFGF) (Ikada and Tabata, 1998), bone morphogenetic protein-2 (BMP-2) (Yamamoto et al., 1998), transforming growth factor beta 1 (TGF- β 1) (Yamamoto et al., 2000), hepatocyte growth factor (HGF) (Ozeki et al., 2001), NK4 plasmid DNA (Kushibiki et al., 2004a), matrix metalloproteinase-1 (MMP-1) plasmid DNA (Aoyama et al., 2003; Lin et al., 2009), small interfering RNA (Nakamura et al., 2008), simvastatin (Tanigo et al., 2010), and cisplatin (Konishi et al., 2003). In addition, gelatin and the water-soluble chemical derivatives have been used to improve the *in vivo* stabilization and targeting of drugs (Kushibiki and Tabata, 2005) as well as form polymer micelles for drug delivery (Tanigo et al., 2010). On the other hand, metal ions, such as Ca^{2+} , Ba^{2+} , Zn^{2+} , and Sr^{2+} ions, have been used as the cross-linker for nanoparticles preparation (Jay and Saltzman, 2009; Jay et al., 2008; Mørch et al., 2006). In addition, about 2 g of zinc ions are known to be present in the adult human body and the ions play an important role in the activity of many metal and metal-activated enzymes (Krebs, 2000).

In this study, a novel delivery system for t-PA where the activity is locally switched on by ultrasound was designed, and the thrombolytic effects were evaluated. As the t-PA carrier, the gelatin and metal ions were used. The complexes of t-PA with the gelatin and metal ions were characterized in terms of the physicochemical properties and the thrombolytic activity. The t-PA activity of complexes was examined before and after ultrasound exposure to assess the potential of ultrasound-induced activity recovery. We examine the retention in the blood

circulation and tissue distribution of t-PA complexes administered intravenously.

MATERIALS AND METHODS

Materials

Gelatin samples with an isoelectric point (IEP) of 9.0 (weight-averaged molecular weight (M_w) = 2,000, 3,000, 5,000, 20,000, 50,000, and 100,000) prepared by an acid process of pig skin type I collagen, were kindly supplied from Nitta Gelatin Inc., Osaka, Japan. Zinc acetate ($\text{Zn}(\text{CH}_3\text{COO})_2$) solution, magnesium acetate ($\text{Mg}(\text{CH}_3\text{COO})_2 \cdot 4\text{H}_2\text{O}$), and calcium acetate ($\text{Ca}(\text{CH}_3\text{COO})_2 \cdot \text{H}_2\text{O}$) were purchased from Nacalai Tesque Inc., Kyoto, Japan. t-PA (Cleactor[®] administration 1,600,000) was purchased from Eisai Co., Ltd., Tokyo, Japan. Chromozym t-PA was purchased from Roche Diagnostics, Germany. Plasmin, plasminogen, and thrombin isolated from the human plasma were obtained from EMD Biosciences Inc., CA. Plasminogen-free fibrinogen from the human plasma was purchased from Sigma-Aldrich Corp., MO. Other chemicals of the purest quality were obtained.

t-PA assay with a peptidic substrate

The hydrolytic activity of t-PA was determined by the conventional assay with a synthetic substrate (Chromozym t-PA, Roche Diagnostics, Germany). Briefly, 20 μl of t-PA solution and 20 μl of different concentrations of zinc acetate were mixed and incubated at 37°C for 30 min. Then, 15 μl of the mixture was added to 150 μl of Chromozym t-PA solution containing 90 mM Tris buffer (pH 8.5) and 0.14 wt% Tween 80. After incubation at 37°C for 30 min, the reaction was stopped by addition of 75 μl of 10 vol% citric acid. The absorbance at 405 nm of the reaction mixture (200 μl) was measured on a microplate reader (VERSAmax, Molecular Devices Co., Ltd., Japan).

1 *Preparation of t-PA complexes with gelatin and metal ions*

2 To prepare the complexes of t-PA and gelatin, 10 mg of gelatin with different molecular
3 weights in 10 mM phosphate-buffered solution (PBS, pH 7.4) (0.25 ml) was mixed with 0.5 ml
4 of PBS containing 0.5 mg of t-PA. After agitation at 37°C for 30 min, different concentrations
5 of zinc acetate, magnesium acetate, or calcium acetate (0.25 ml) were added to the mixture,
6 followed by agitation at 37°C for 30 min to prepare the complex of t-PA with gelatin and metal
7 ions.

9 *Measurement of apparent molecular size of t-PA complexes with gelatin and zinc ions*

10 The apparent molecular size of t-PA complexes with gelatin and zinc ions was measured by
11 dynamic light scattering (DLS) apparatus (DLS-7000, Otsuka Electronic, Osaka, Japan)
12 equipped with an Ar⁺ laser at a detection angle of 90° at 37°C. The autocorrelation function of
13 samples was analyzed based on the histogram method and R_s value was calculated
14 automatically by the equipped computer software. The experiments were done 3 times
15 independently for each sample.

17 *Assay of t-PA activity by fibrin plate method*

18 To determine the *in vitro* thrombolytic activity of t-PA, a fibrin clot lysis assay was
19 performed according to the conventional plasminogen-rich fibrin plate method (Astrup and
20 Müllertz, 1952). Briefly, 0.4 wt% human fibrinogen solution (10 ml) in 0.17 M borate buffer
21 (pH 7.8) was poured into a 10-cm petri dish (Flat). Plasminogen (0.2 ml, 50 U/ml) was added to
22 the fibrinogen solution. Clotting was induced by adding 0.2 ml of human thrombin (100 U/ml),
23 followed by leaving for 30 min at room temperature to allow the clot formation. Then, 2 µl of
24 PBS solution containing t-PA or t-PA complexes with gelatin and metal ions was carefully
25 placed onto the plate. After incubation at 37°C for 1 hr, the diameter of clear zones was

measured while the standard curve between the diameter and the activity was prepared using human plasmin at determined concentrations. The percent activity was calculated as the percentage of sample activity to that of free t-PA. The experiment was done at least 3 times independently for each sample.

To evaluate the t-PA activity in bovine serum albumin (BSA) solution, the similar assay procedure was performed except that various solutions of t-PA complex were incubated with 42 mg/ml of BSA for 90 min at 37°C before the t-PA activity assay.

To evaluate the t-PA activity before and after ultrasound irradiation *in vitro*, various solutions of t-PA complex were treated with continuous wave ultrasound at 1 MHz with an intensity of 0.75 W/cm² for 5 min. Then, the t-PA activity of solution exposed to ultrasound was similarly evaluated to compare with that of untreated solution.

Cell viability

Cytotoxicity was assayed for mouse fibroblast L929 cells by using a cell counting kit (Nacalai Tesque Inc., Kyoto, Japan). The cells were seeded on each well of 96-well cell culture dish (Corning Inc., NY) at a density of 5000 cells/100 µl per a well and cultivated in Eagle's MEM (E-MEM) medium containing 10 vol% fetal calf serum (FCS) for 24 hr at 37°C in 5% CO₂ –95% air atmosphere. The medium was changed to 90 µl of the fresh medium, and then 10 µl of PBS solution containing complexes of t-PA with gelatin and zinc ions was applied to each well, followed by incubation for 48 hr. Then, the medium was changed to 100 µl of E-MEM medium containing 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8) and incubated further for 2 hr. The absorbance of medium was measured at 450 nm by the VERSAmax microplate reader (Molecular Devices, Sunnyvale CA). The percentage of cell viability was expressed as 100% for non-treated cells. The experiment was done 6 times

independently for each sample.

Body distribution tests of t-PA complexes with gelatin and zinc ions

The body distribution of complexes of t-PA with gelatin and zinc ions was evaluated for 6-week-old female ddY mice (Simizu Laboratory Supplies Co., Ltd., Kyoto, Japan) as described previously (Kushibiki et al., 2004b). Briefly, t-PA was radioiodinated according to the chloramine T method (Wilbur et al., 1989). The t-PA complexes were similarly prepared by the procedure described above other than using ^{125}I -labeled t-PA. The ^{125}I -labeled t-PA and the complexes with gelatin and zinc ions were administered into the tail vein of mice in a PBS volume of 100 μl . At different time intervals after administration, the blood samples were collected from the eye orbit. The radioactivity of blood was counted on the gamma counter (ARC-301B, Aloka, Tokyo, Japan). The percentage of radioactivity remaining was expressed as 100% for the radioactivity of t-PA initially administrated.

At 60 min after administration, the mice were sacrificed and their tissues and organs were excised and rinsed quickly with cold water to remove the surface blood. Then, the radioactivity of tissues and organs was counted as described above. The animal experiments were carried out according to the Institutional Guidance of Kyoto University on Animal Experimentation. The experiment was done 6 times independently for each sample at each time point.

Statistical analysis

The statistical analysis was performed using an unpaired Student's *t* test. All the data were presented as the mean $\pm$ the standard deviation (SD).

1 RESULTS

2 *Characterization of t-PA complexes with gelatin and zinc ions*

3 Figure 1 shows the apparent molecular size of gelatin with different molecular weights, the
4 complexes of t-PA and zinc ions. The apparent molecular size of gelatins with molecular
5 weights ranging from 2,000 to 5,000 could not be measured because of their too small size. The
6 molecular weight size of gelatin tended to increase with the increased molecular weight. The
7 apparent molecular size of gelatin was increased by the addition of zinc ions. Irrespective of the
8 molecular weight of gelatin, the apparent molecular size was dramatically changed by mixing
9 with t-PA and zinc ions. The size of t-PA complexes tended to decrease with an increase in the
10 molecular weight of gelatin.

11

12 *Thrombolytic activity of t-PA complexes with gelatin and zinc ions*

13 Figure 2 shows the t-PA activity change by the complexation with gelatin of different
14 molecular weights and zinc ions. Irrespective of the gelatin molecular weight, the thrombolytic
15 activity of t-PA was significantly suppressed by the complexation with gelatin and zinc ions
16 (Figure 2A). The suppression tended to become stronger with a decrease in the molecular
17 weight of gelatin. Figure 2B shows the t-PA activity change of complexes with gelatins and
18 zinc ions in the presence of BSA. Interestingly, the suppression was weaker with a decrease in
19 the molecular weight of gelatin. From the viewpoint of activity suppression, the following
20 experiment was performed for the gelatin with a molecular weight of 100,000. Figure 3 shows
21 change in the t-PA activity by complexing with zinc ions and gelatin at different concentrations.
22 The activity of t-PA complexes tended to decrease with an increase in the concentration of
23 gelatin, and then leveled off at the gelatin concentrations of 10 mg/ml and higher. When
24 fractionated by a gel filtration column, the t-PA containing ratio of t-PA complexes at the
25 gelatin concentrations of 10 mg/ml was approximately 84%.

Effect of metal ions on thrombolytic activity of t-PA complexes with gelatin

Figure 4 shows the activity change of t-PA by complexation with gelatin and various types of metal ions. The t-PA activity was significantly suppressed by complexing with gelatin and every metal ions tested in this study (Figures 4A-C), although the t-PA activity was not suppressed by complexation with gelatin alone (data not shown). The suppression extent increased in a dose-dependent manner. Among zinc, magnesium, and calcium ions, the thrombolytic activity of complexes was suppressed most strongly with zinc ions. In addition, the stability of t-PA complexes with magnesium and calcium ions in serum was lower than that with zinc ions (data not shown). After ultrasound exposure, the suppressed t-PA activity of gelatin and zinc ions complexes was recovered to the level of original t-PA activity at the zinc concentrations of 5 mM or lower (Figure 4D).

Figure 5 shows the activity of t-PA in the presence of zinc ions at different concentrations. No decrease in the t-PA activity was observed at the zinc concentrations of 5 mM and lower.

Figure 6 shows the t-PA activity change of complexes by addition of different concentrations of EDTA, metal chelator. The suppressed t-PA activity of complexes tended to increase with an increase in the concentration of EDTA.

Cell viability of t-PA complexes with gelatin and zinc ions

Figure 7A shows the cytotoxicity of t-PA complexes with gelatin and zinc ions. The complexes showed over 90% cell viability at the concentrations of 200 μ g/ml and lower. However, the cell viability gradually decreased at the concentrations of 300 μ g/ml and higher. Zinc ions, gelatin, and t-PA alone showed over 90% cell viability at the concentrations of 50 μ M, 500 μ g/ml, 50 μ g/ml and lower, respectively (Figures 7B, C). The concentration of zinc ions, gelatin, and t-PA used for complexation in the *in vivo* experiment were 2 μ M, 4 μ g/ml, and 0.2 μ g/ml, respectively, which is much lower than those of cytotoxicity.

1 *Body distribution of t-PA and t-PA complexes with gelatin and zinc ions*

2 Figure 8A shows the percentage of radioactivity remaining in the blood circulation
3 following intravenous administration of ^{125}I -labeled t-PA and the complexes. The radioactivity
4 remaining was significantly higher for the complexes of gelatin and zinc ions than that of free
5 t-PA over the time range studied. The blood concentration of free t-PA was rapidly reduced
6 after administration. Complexation with gelatin and zinc ions prolonged the blood half-life of
7 t-PA about 3 times. Figure 8B shows the tissue distribution of t-PA complexes with gelatin and
8 zinc ions or free t-PA. The similar body distribution pattern was observed between the two
9 groups.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 DISCUSSION

2 Several DDS trials of t-PA have been reported for the thrombotic diseases of myocardial
3 infarction and ischemic stroke with various carriers. Liposomes encapsulating t-PA
4 (Tiukinhoy-Laing et al., 2007; Shaw et al., 2009; Heeremans et al., 1995; Smith et al., 2010), or
5 poly-(lactide-co-glycolide) microspheres incorporating t-PA and coated with Arg-Gly-Asp
6 peptide, which is a minimal cell-recognizable peptide of adhesion protein, significantly
7 accelerated thrombolysis *in vitro* (Chung et al., 2008). Combination of t-PA with microbubble
8 induced the acceleration of ultrasound-enhanced thrombolysis in a model of acute stroke
9 (Molina et al., 2006; Collis et al., 2010).

10 This study is undertaken to design a novel ultrasound-responsive t-PA delivery system with
11 gelatin and zinc ions. Gelatin has been used for the controlled release of various drugs, proteins,
12 and genes because of the good biodegradability and biocompatibility (Veis, 1965; Ikada and
13 Tabata, 1998; Yamamoto et al., 1998, 2000; Ozeki et al., 2001; Kushibiki et al., 2004a; Aoyama
14 et al., 2003; Lin et al., 2009; Nakamura et al., 2008; Tanigo et al., 2010; Konishi et al., 2003).
15 The thrombolytic activity of t-PA was suppressed by the complexation with gelatin and zinc
16 ions under the optimal condition, and recovered only when exposed to ultrasound. This
17 ultrasound-induced recovery of t-PA activity is an ideal system considering several problems to
18 be resolved clinically, such as the bleeding complication and the short half-life *in vivo*.

19 t-PA is a globular protein with an molecular weight of about 70,000 (Rijken and Lijnen,
20 2008; Hedstrom, 2002) and the zeta potential is negative (data not shown). Therefore, it is
21 expected that the t-PA molecule can electrostatically interact with gelatin (IEP = 9.0). The K_D
22 value between gelatin and t-PA was measured to be 7.01×10^{-8} M by the quartz crystal
23 microbalance analysis. For example about specific interaction, previous surface plasmon
24 resonance analysis indicated that K_D between the collagen-binding domain (CBD) from
25 *Clostridium histolyticum* collagenase and mini-collagen peptide was 5.72×10^{-5} M (Wilson et

al., 2003). These results suggested that the interaction of t-PA and gelatin molecules for complexation was stronger than that of specific interaction between the CBD and the collagen peptide. However, the t-PA activity was not suppressed by complexation with gelatin (data not shown). It is highly conceivable that the t-PA molecules do not always interact with gelatin in the manner to biologically suppress the t-PA activity. Therefore, metal ions were added to modify the interaction between the gelatin and t-PA molecules.

The analysis on the nonredundant proteins structures from the Protein Data Bank showed that the most abundant metal ion in the body is Mg^{2+} , followed by Zn^{2+} , Ca^{2+} , Fe^{2+} , Mn^{2+} , Cd^{2+} , Cu^{2+} , Co^{2+} , and Ni^{2+} (Dokmanić et al., 2008). Based on this, considering the toxicity nature (Yamamoto et al., 2004), Mg^{2+} , Zn^{2+} , and Ca^{2+} ions were tested in this study (Figure 4). The t-PA activity of complexes was most strongly suppressed by the addition of Zn^{2+} ions. It is likely that the t-PA and gelatin molecules of complexes was modified by a coordinate bond and an ionic bond with Zn^{2+} ions, whereas they were done by an ionic bond with Mg^{2+} and Ca^{2+} ions. The apparent molecular size of gelatin was dramatically changed by t-PA and Zn^{2+} ions complexation. It tended to increase with a decrease in the molecular weight (Figure 1). The thrombolytic activity of t-PA tended to suppress more strongly by the complexion with gelatin and zinc ions when the molecular weight of gelatin decreased (Figure 2A). The SDS-PAGE analysis and atomic absorption photometer revealed that the complexes of gelatin and t-PA, when fractionated by a gel filtration column, were contained zinc ions (data not shown). Moreover, no decrease in the t-PA activity was observed at the zinc concentrations of 5 mM and lower (Figure 5). With gelatin molecules, the t-PA activity was suppressed at low concentrations of zinc ions, although the t-PA activity was maintained without gelatin. Additionally, the suppression extent of t-PA activity tended to increase with an increase in the concentration of gelatin (Figure 3). Taken together, we can say with certainty that the interaction between the t-PA and gelatin molecules can be reinforced by mixing zinc ions,

resulting in the suppressed biological activity. The amino acid residues contributing to the coordination bonds with zinc ions are Cys, His, Asp, and Glu in the metalloproteins (Dokmanić et al., 2008). For the present t-PA complexes, the carboxyl, hydroxyl, and amino groups of gelatin and t-PA were considered to contribute to the coordination bond with zinc ions, while the carboxyl groups also contribute to the ionic bond. Taken together, it is highly speculated that t-PA molecules electrostatically interact with gelatin ones to form their complex, and additionally, the complex becomes stable through the coordination bond with zinc ions between the carboxyl, hydroxyl, and amino groups of the two proteins.

The t-PA activity of complexes depended on the molecular weight of gelatin used (Figure 2). This can be explained by the mobility of gelatin molecules. The molecular mobility of lower molecular weight gelatin to interact is high compared with that of higher molecular weight gelatin. Therefore, it is highly conceivable that the t-PA molecules of negative charge interact more with smaller gelatin molecules of positive charge, resulting in the larger molecular size of t-PA complexes (Figure 1). The more interaction would cover t-PA molecules more to suppress the activity to a higher extent (Figure 2A). However, the effect of gelatin molecular weight on the t-PA activity in the presence of BSA was different. The smaller gelatin showed the higher percent t-PA activity (Figure 2B). This suggests that the BSA presence enabled the t-PA–gelatin complexes to dissociate. The electrostatic interaction between smaller gelatin and t-PA molecules is weaker than that of larger gelatin ones. In addition, the smaller gelatin molecules have the higher mobility. As the result, it is likely that small gelatin are readily detached from the t-PA molecules and bound to BSA ones. On the other hand, it is demonstrated that albumin has a high-affinity zinc binding site consisting of His67 and Asn99 from domain I and His247 and Asp249 from domain II (Lu et al., 2008; Stewart et al., 2003). This binding may allow the gelatin and BSA interaction to stabilize, resulting in the increased existence of free t-PA. Based on the stability of t-PA–gelatin complexes in the solution, the

molecular weight of gelatin 100,000 was selected for the t-PA complexes formation.

It is apparent in Figure 4D that the ultrasound irradiation allowed the t-PA activity to recover to the original level. This is because the interaction forces between the t-PA and gelatin molecules in the presence of zinc ions were not so strong to allow dissociation by the ultrasound stimulus. In addition, the ultrasound irradiation did not lose the t-PA activity. In this study, the conditions of ultrasound were a frequency of 1 MHz and an intensity of 0.75 W/cm^2 in *in vitro* experiments. To date, various ultrasound energy levels ($0.2\text{--}16 \text{ W/cm}^2$) and frequencies (20 kHz–2 MHz) have been used for thrombolysis (Tsivgoulis et al., 2008; Ishibashi et al., 2002). The majority of studies used of 1 MHz both *in vitro* and *in vivo* (Ishibashi et al., 2002), and the frequency is typically lower than that of diagnostic applications. Recently, 1 MHz and 0.75 W/cm^2 ultrasound significantly enhanced tPA-induced pharmacological lysis of platelet-rich thrombus (recanalization ratio; 90%) with no distal embolization by fragmented thrombi (Kawata et al., 2007). Taken together, the present ultrasound conditions will be safe and effective for sonothrombolysis in the femoral artery model.

It is recognized that some metal ions sometimes show cytotoxicity. Yamamoto et al. evaluated 43 metal salts for cytotoxicity using MC3T3-E1 and L929 cells (Yamamoto et al., 2004). $\text{K}_2\text{Cr}_2\text{O}_7$, CdCl_2 , VCl_3 , AgNO_3 , HgCl_2 , SbCl_3 , BeSO_4 , and InCl_3 are high toxic salts in which IC_{50} s are smaller than $10^{-5} \text{ mol L}^{-1}$ for both or either of the cell lines. The cytotoxicity experiments demonstrated that the complexes with zinc ions showed almost no cytotoxicity even at a gelatin concentration of $200 \text{ }\mu\text{g/ml}$ (Figure 7). The concentration of t-PA, gelatin, and Zn ions used for complexation in the *in vivo* experiment were $0.2 \text{ }\mu\text{g/ml}$, $4 \text{ }\mu\text{g/ml}$, and $2 \text{ }\mu\text{M}$, respectively, which is much lower than those of cytotoxicity. At the concentration of t-PA, gelatin, or Zn ions alone, no cytotoxicity was observed. It is conceivable that upon ultrasound exposure, the components of complex and their combinations are released out. I do not think

that the combination of components brings about any cytotoxicity. Therefore, we believe that the t-PA complexes with gelatin and Zn ions after the application of ultrasound irradiation have no cytotoxicity in the *in vivo* experiment.

The t-PA used in this study is mutant t-PA, monteplase (Verstraete, 1999; Inoue et al., 2004), where Cys84 is substituted with Ser in the epidermal growth factor domain of human t-PA. It is reported that the half-life is about 20 min (Verstraete, 1999), which is similar to the present result (Figure 8A). The complexation with the gelatin and zinc ions enabled t-PA to prolong the half-life in the blood circulation. This is because the apparent molecular size of t-PA was reduced by the complexation. Complexing with the gelatin and zinc ions, the apparent molecular size of t-PA became 95 nm (Figure 1). It is reported that the size of long-circulating particles should not exceed 200 nm (Moghimi et al., 2001). In addition, the resistance of t-PA against enzymatic degradation will also be increased by the gelatin complexation. Generally, the biological activity of proteins is protected from enzymatic attack through their modifications with polymer carriers (Sehgal and Srinivasan, 2009). The *in vitro* stability of t-PA in the mouse serum significantly increased by complexing with gelatin and zinc ions with the molecular weight of gelatin 20,000 or higher (data not shown). The complexes administered intravenously retained in the blood circulation for prolonged time periods, while the *in vivo* stability of t-PA was enhanced due to an increased resistance against enzymatic degradation. It has been reported that proteins and peptides encapsulated in poly(lactic/glycolic acid) microparticles are stabilized by their complexing with zinc ions (Schwendeman, 2002; Lam et al., 2001; Carino et al., 2000; Lam et al., 2000; Yamagata et al., 2003). In addition, the coordination bonds with zinc ions contribute to the stabilization of endostatin and α -crystallin structures (Han et al., 2007; Biswas and Das, 2008).

Drug delivery from alginate microparticles cross-linked with Zn^{2+} and Ca^{2+} ions has been investigated (George and Abraham, 2006; Jay and Saltzman, 2009; Jay et al., 2008; Colinet et

al., 2009; Chueh et al., 2010). The pH- and UV-sensitive alginate hydrogels cross-linked with calcium ions were reported (Colinet et al., 2009; Chueh et al., 2010). However, ultrasound-responsive carriers modified with metal ions have not been reported. The present study clearly demonstrates that the metal ions modification was effective in the stabilization of ultrasound-responsive drug carrier through the cross-linking. Many ultrasound-triggered drug release with other systems, such as pluronic micelles (Rapoport et al., 2002; Marin et al., 2001), acoustically active liposomes (Daocheng and Mingxi, 2008), the fluoride anion modified with a gelatin nanogel (Frinking et al., 1998), have been reported. Tiukinhoy-Laing *et al.* reported that t-PA loaded-echogenic liposomes increased 1.5 times of clot lysis with the t-PA loaded-liposome alone by ultrasound at 1 MHz and 2 W/cm² for 2 min (Tiukinhoy-Laing et al., 2007). In this study, t-PA complexes with gelatin and zinc ions increased about 2 times of t-PA activity compared with the original level by ultrasound at 1 MHz and 0.75 W/cm² for 5 min. It is highly speculated that the ultrasound power dissociates the interaction of t-PA and gelatin complexes by cavitation effect which generates shock waves and high-speed fluid microjets (Deckers et al., 2008). From the data comparison, we can say that our delivery system is a sensitive and effective ultrasound-responsive system. For the t-PA complexes at the optimal concentration of zinc ions, the t-PA activity could be recovered by ultrasound irradiation. In the previous study, free t-PA administration with or without ultrasound was effective in recanalization, although there were the adverse effects to be resolved (Kawata et al., 2007). On the contrary, the complexation with gelatin will suppress the adverse effect of t-PA. The t-PA activity is suppressed, but locally recovered upon the ultrasound irradiation around the site necessary.

Combination of a thrombolytic agent and ultrasound enhanced thrombolysis for stroke and acute myocardial infarction (Alexandrov et al., 2004; Eggers et al., 2003; Cohen et al., 2003). In the investigations, it is suggested that the direct transmission of energy and the acoustic

cavitation with low-frequency and high-intensity ultrasound broke clots into small fragments (Rosenschein et al., 1994), promote the penetration of t-PA molecules into the thrombus, the radiation force to facilitate the reformation, and opening of fibrin matrix, and enhance the drug diffusion, and the direct effects on the binding of t-PA to the fibrin clot are the mechanisms of ultrasound on the enhanced thrombolysis (Tiukinhoy-Laing et al., 2007). In the future, we plan further studies of evaluation of the thrombolytic effect of t-PA complexes with or without the local ultrasound irradiation around the infarction site of blood vessels in rabbit and swine thrombosis models.

CONCLUSION

Novel and promising ultrasound-responsive nano gelatin complexes of t-PA stabilized by zinc ions were designed. This system is safe, simple, and convenient to permit the treatment of acute myocardial infarction while performing diagnosis at the same time even in emergency conditions. Moreover, the delivery system is also applicable to other therapeutic drugs for the medical treatment of various diseases.

ACKNOWLEDGMENT

This study was financially supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO) (project ID; 06-14).

1 REFERENCES

- 2 Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J,
3 Saqqur M, Demchuk AM., Moyé LA, Hill MD, Wojner AW; CLOTBUST Investigators.
4 (2004). Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. *N Engl J*
5 *Med*, 351, 2170–2178.
- 6 Aoyama T, Yamamoto S, Kanematsu A, Ogawa O, Tabata Y. (2003). Local delivery of matrix
7 metalloproteinase gene prevents the onset of renal sclerosis in streptozotocin-induced
8 diabetic mice. *Tissue Eng*, 9, 1289–1299.
- 9 Armstrong PW, Collen D. (2001). Fibrinolysis for acute myocardial infarction: current status
10 and new horizons for pharmacological reperfusion. *Circulation*, 103, 2862–2866.
- 11 Astrup T, Müllertz S. (1952). The fibrin plate method for estimating fibrinolytic activity. *Arch*
12 *Biochem Biophys*, 40, 346–351.
- 13 Biswas A, Das KP. (2008). Zn²⁺ enhances the molecular chaperone function and stability of
14 alpha-crystallin. *Biochemistry*, 47, 804-816.
- 15 Blann AD, Landray ML, Lip GY. (2002). An overview of antithrombotic therapy. *BMJ*, 325,
16 762–765.
- 17 Bode C, Runge MS, Smalling RW. (1996). The future of thrombolysis in the treatment of acute
18 myocardial infarction. *Eur Heart J*, 17, 55–60.
- 19 Carino GP, Jacob JS, Mathiowitz E. (2000). Nanosphere based oral insulin delivery. *J Control*
20 *Release*, 65, 261-269.
- 21 Chueh BH, Zheng Y, Torisawa YS, Hsiao AY, Ge C, Hsiong S, Huebsch N, Franceschi R,
22 Mooney DJ, Takayama S. (2010). Patterning alginate hydrogels using light-directed
23 release of caged calcium in a microfluidic device. *Biomed Microdevices*, 12, 145-151.
- 24 Chung TW, Wang SS, Tsai WJ. (2008). Accelerating thrombolysis with chitosan-coated
25 plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.

- 1 Biomaterials, 29, 228–237.
- 2 Cohen MG, Tuero E, Blughermann J, Kevorkian R, Berrocal DH, Carlevaro O, Picabea E,
- 3 Hudson MP, Siegel RJ, Douthat L, Greenbaum AB, Echt D, Weaver WD, Grinfeld LR.
- 4 (2003). Transcutaneous ultrasound-facilitated coronary thrombolysis during acute
- 5 myocardial infarction. *Am J Cardiol*, 92, 454–457.
- 6 Colinet I, Dulong V, Mocanu G, Picton L, Le Cerf D. (2009). New amphiphilic and
- 7 pH-sensitive hydrogel for controlled release of a model poorly water-soluble drug. *Eur J*
- 8 *Pharm Biopharm*, 73, 345-350.
- 9 Collis J, Manasseh R, Liovic P, Tho P, Ooi A, Petkovic-Duran K, Zhu Y. (2010). Cavitation
- 10 microstreaming and stress fields created by microbubbles. *Ultrasonics*, 50, 273–279.
- 11 Daocheng W, Mingxi W. (2008). A novel fluoride anion modified gelatin nanogel system for
- 12 ultrasound-triggered drug release. *J Pharm Pharmaceut Sci*, 11, 32–45.
- 13 Deckers R, Rome C, Moonen CT. (2008). The role of ultrasound and magnetic resonance in
- 14 local drug delivery. *J Magn Reson Imaging*, 27, 400-409.
- 15 Dokmanić I, Sikić M, Tomić S. (2008). Metals in proteins: correlation between the metal-ion
- 16 type, coordination number and the amino-acid residues involved in the coordination. *Acta*
- 17 *Crystallogr D Biol Crystallogr*, 64, 257-263.
- 18 Eggers J, Koch B, Meyer K, Konig I, Seidel G. (2003). Effect of ultrasound on thrombolysis of
- 19 middle cerebral artery occlusion. *Ann Neurol*, 53, 797–800.
- 20 Frinking PJ, Bouakaz A, de Jong N, Ten Cate FJ., Keating S. (1998). Effect of ultrasound on
- 21 the release of micro-encapsulated drugs. *Ultrasonics*, 36, 709–712.
- 22 George M, Abraham TE. (2006). Polyionic hydrocolloids for the intestinal delivery of protein
- 23 drugs: alginate and chitosan--a review. *J Control Release*, 114, 1-14.
- 24 Han Q, Fu Y, Zhou H, He Y, Luo Y. (2007). Contributions of Zn(II)-binding to the structural
- 25 stability of endostatin. *FEBS Lett*, 581, 3027-3032.

- 1 Hedstrom L. (2002). Serine protease mechanism and specificity. *Chem Rev*, 102, 4501–4523.
- 2 Heeremans JL, Prevost R, Bekkers ME, Los P, Emeis JJ, Kluft C, Crommelin DJ. (1995).
- 3 Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing
- 4 liposomes in rabbits: a comparison with free t-PA. *Thromb Haemost*, 73, 488–494.
- 5 Huang SL, MacDonald RC. (2004). Acoustically active liposomes for drug encapsulation and
- 6 ultrasound-triggered release. *Biochim Biophys Acta*, 1665, 134–141.
- 7 Ikada Y, Tabata Y. (1998). Protein release from gelatin matrices. *Adv Drug Deliv Rev*, 31,
- 8 287–301.
- 9 Inoue T, Nishiki R, Kageyama M, Node K. (2004). Therapeutic potential of monteplase in
- 10 acute myocardial infarction as a powerful thrombolytic agent for pretreatment of coronary
- 11 intervention. *Cardiovasc. Drug Rev*, 22, 320-333.
- 12 Ishibashi T, Akiyama M, Onoue H, Abe T, Furuhata H. (2002). Can transcranial ultrasonication
- 13 increase recanalization flow with tissue plasminogen activator? *Stroke*, 33, 1399–1404.
- 14 Jay SM, Shepherd BR, Bertram JP, Pober JS, Saltzman WM. (2008). Engineering of
- 15 multifunctional gels integrating highly efficient growth factor delivery with endothelial
- 16 cell transplantation. *FASEB J*, 22, 2949–2956.
- 17 Jay SM, Saltzman WM. (2009). Controlled delivery of VEGF via modulation of alginate
- 18 microparticle ionic crosslinking. *J Control Release*, 134, 26–34.
- 19 Kawata H, Naya N, Takemoto Y, Uemura S, Nakajima T, Horii M, Takeda Y, Fujimoto S,
- 20 Yamashita A, Asada Y, Saito Y. (2007). Ultrasound accelerates thrombolysis of acutely
- 21 induced platelet-rich thrombi similar to those in acute myocardial infarction. *Circ J*, 71,
- 22 1643–1648.
- 23 Konishi M, Tabata Y, Kariya M, Suzuki A, Mandai M, Nanbu K, Takakura K, Fujii S. (2003).
- 24 In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable
- 25 gelatin hydrogel. *J Control Release*, 92, 301–313.

- 1 Krebs NF. (2000). Overview of Zinc Absorption and Excretion in the Human Gastrointestinal
- 2 Tract. *J Nutr*, 130 (5S Suppl), 1374S–1377S.
- 3 Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. (2004a). Suppression of the progress of
- 4 disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized
- 5 gelatin microspheres. *Pharm Res*, 21, 1109–1118.
- 6 Kushibiki T, Matsuoka H, Tabata Y. (2004b). Synthesis and physical characterization of
- 7 poly(ethylene glycol)-gelatin conjugates. *Biomacromolecules*, 5, 202–208.
- 8 Kushibiki T, Tabata Y. (2005). Preparation of poly(ethylene glycol)-introduced cationized
- 9 gelatin as a non-viral gene carrier. *J Biomater Sci Polym Ed*, 16, 1447–1461.
- 10 Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. (2000). Sustained release of
- 11 recombinant human insulin-like growth factor-I for treatment of diabetes. *J Control*
- 12 *Release*, 67, 281-292.
- 13 Lam XM, Duenas ET, Cleland JL. (2001). Encapsulation and stabilization of nerve growth
- 14 factor into poly(lactic-co-glycolic) acid microspheres. *J Pharm Sci*, 90, 1356-1365.
- 15 Lin X, Jo H, Ishii TM, Fujita M, Fu M, Tambara K, Yamamoto M, Tabata Y, Komeda M,
- 16 Matsuoka S. (2009). Controlled release of matrix metalloproteinase-1 plasmid DNA
- 17 prevents left ventricular remodeling in chronic myocardial infarction of rats. *Circ J*, 73,
- 18 2315–2321.
- 19 Lu J, Stewart AJ, Sadler PJ, Pinheiro TJ, Blindauer CA. (2008). Albumin as a zinc carrier:
- 20 properties of its high-affinity zinc-binding site. *Biochem Soc Trans*, 36, 1317-1321.
- 21 Marin A, Muniruzzaman M, Rapoport N. (2001). Mechanism of the ultrasound activation of
- 22 micellar drug delivery. *J Control Release*, 75, 69–81.
- 23 Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific
- 24 nanoparticles: theory to practice. *Pharm Res*, 53, 283–318.
- 25 Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, Arenillas JF,

- 1 Huertas R, Purroy F, Delgado P, Alvarez-Sabín J. (2006). Microbubble administration
- 2 accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients
- 3 treated with intravenous tissue plasminogen activator. *Stroke*, 37, 425–429.
- 4 Mørch YA, Donati I, Strand BL, Skjåk-Braek G. (2006). Effect of Ca^{2+} , Ba^{2+} , and Sr^{2+} on
- 5 alginate microbeads. *Biomacromolecules*, 7, 1471–1480.
- 6 Nakamura M, Jo J, Tabata Y, Ishikawa O. (2008). Controlled delivery of T-box21 small
- 7 interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse
- 8 model. *Am J Pathol*, 172, 650–658.
- 9 Ozeki M, Ishii T, Hirano Y, Tabata Y. (2001). Controlled release of hepatocyte growth factor
- 10 from gelatin hydrogels based on hydrogel degradation. *J Drug Target*, 9, 461–471.
- 11 Rapoport N, Marin A, Christensen D. (2002). Ultrasound activation micellar drug delivery.
- 12 *Drug Deliv Sys Sci*, 2, 37–46.
- 13 Rijken DC, Lijnen HR. (2008). New insights into the molecular mechanisms of the fibrinolytic
- 14 system. *J Thromb Haemost*, 7, 4–13.
- 15 Rosenschein U, Frimerman A, Laniado S, Miller HI. (1994). Study of the mechanism of
- 16 ultrasound angioplasty from human thrombi and bovine aorta. *Am J Cardiol*, 74,
- 17 1263-1266.
- 18 Schwendeman SP. (2002). Recent advances in the stabilization of proteins encapsulated in
- 19 injectable PLGA delivery systems. *Crit Rev Ther Drug Carrier Syst*, 19, 73-98.
- 20 Sehgal PK, Srinivasan A. (2009). Collagen-coated microparticles in drug delivery. *Expert Opin*
- 21 *Drug Deliv*, 6, 687–695.
- 22 Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK. (2009).
- 23 Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. *Thromb Res*,
- 24 124, 306–310.
- 25 Smith DA, Vaidya SS, Kopechek JA, Huang SL, Klegerman ME, McPherson DD, Holland CK.

- 1 (2010). Ultrasound-triggered release of recombinant tissue-type plasminogen activator
- 2 from echogenic liposomes. *Ultrasound Med Biol*, 36, 145–157.
- 3 Stewart AJ, Blindauer CA, Berezenko S, Sleep D, Sadler PJ. (2003). Interdomain zinc site on
- 4 human albumin. *Proc Natl Acad Sci U S A*, 100, 3701-3706.
- 5 Tanigo T, Takaoka R, Tabata Y. (2010). Sustained release of water-insoluble simvastatin from
- 6 biodegradable hydrogel augments bone regeneration. *J Control Release*, 143, 201–206.
- 7 Tiukinhoy-Laing SD, Huang S, Klegerman M, Holland CK, McPherson DD. (2007).
- 8 Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic
- 9 liposomes. *Thromb Res*, 119, 777–784.
- 10 Tsivgoulis G, Culp WC, Alexandrov AV. (2008). Ultrasound enhanced thrombolysis in acute
- 11 arterial ischemia. *Ultrasound*, 48, 303–311.
- 12 Turpie AG, Chin BS, Lip GY. (2002). Venous thromboembolism: treatment strategies. *BMJ*,
- 13 325, 948–950.
- 14 Veis A. (1965). The physical chemistry of gelatin. *Int. Rev. Connect. Tissue Res*, 3, 113–200.
- 15 Verstraete M. (1999). Newer thrombolytic agents. *Ann Acad Med Singapore*, 28, 424–433.
- 16 Wilbur DS, Hadley SW, Hylarides MD, Abrams PG, Beaumier PA, Morgan AC, Reno JM,
- 17 Fritzberg AR. (1989). Development of a stable radioiodinating reagent to label monoclonal
- 18 antibodies for radiotherapy of cancer. *J Nucl Med*, 30, 216–226.
- 19 Wilson JJ, Matsushita O, Okabe A, Sakon J. (2003). A bacterial collagen-binding domain with
- 20 novel calcium-binding motif controls domain orientation. *EMBO J*, 22, 1743–1752.
- 21 Yamagata Y, Misaki M, Kurokawa T, Taira K, Takada S. (2003). Preparation of a copoly
- 22 (dl-lactic/glycolic acid)-zinc oxide complex and its utilization to microcapsules containing
- 23 recombinant human growth hormone. *Int J Pharm*, 251, 133-141.
- 24 Yamamoto A, Honma R, Sumita M, Hanawa T. (2004). Cytotoxicity evaluation of ceramic

particles of different sizes and shapes. J Biomed Mater Res A, 68, 244–256.

Yamamoto M, Tabata Y, Ikada Y. (1998). Ectopic bone formation induced by biodegradable hydrogels incorporating bone morphogenetic protein. J Biomater Sci Polym Ed, 9, 439–458.

Yamamoto M, Tabata Y, Hong L, Miyamoto S, Hashimoto N, Ikada Y. (2000). Bone regeneration by transforming growth factor beta1 released from a biodegradable hydrogel. J Control Release, 64, 133–142.

1 FIGURE LEGENDS

2 **Figure 1.** The apparent molecular size of gelatin with different molecular weights (final
3 concentration: 10 mg/ml) and the complexes of t-PA (0.5 mg/ml) and zinc ions (5 mM) : (○)
4 t-PA complexes with gelatin and zinc ions, (●) gelatin complexes with zinc ions, and (Δ) free
5 gelatin.

6
7 **Figure 2.** Change in the t-PA activity by complexing with gelatin (10 mg/ml) and zinc ions (5
8 mM) as a function of gelatin molecular weight in PBS (A) or BSA solution (B). The percent
9 t-PA activity was expressed as 100% for free t-PA without zinc ions. *, $P < 0.05$; significant
10 against the activity of free t-PA.

11
12 **Figure 3.** Change in the t-PA activity of complexes with different concentrations of gelatin
13 ($M_w = 100,000$), t-PA (0.5 mg/ml), and zinc ions (5 mM). The percent t-PA activity was
14 expressed as 100% for free t-PA without zinc ions. *, $P < 0.05$; significant against the activity
15 of free t-PA.

16
17 **Figure 4.** Change in the t-PA activity of complexes with gelatin ($M_w = 100,000$, 10 mg/ml) and
18 zinc (A), magnesium (B), and calcium ions (C) at different concentrations. (D) Change in the
19 t-PA activity of t-PA complexes of gelatin and zinc ions by ultrasound irradiation. The percent
20 t-PA activity was expressed as 100% for free t-PA without zinc ions. *, $P < 0.05$; significant
21 against the activity of free t-PA (t-PA).

22
23 **Figure 5.** The activity of t-PA (0.5 mg/ml) in the presence of zinc ions at different
24 concentrations. The percent t-PA activity was expressed as 100% for free t-PA without zinc
25 ions. *, $P < 0.05$; significant against the activity of free t-PA.

Figure 6. Effect of EDTA addition on the t-PA activity of complexes with gelatin ($M_w = 100,000$, 10 mg/ml) and zinc ions (5 mM). The percent t-PA activity was expressed as 100% for free t-PA without zinc ions. *, $P < 0.05$; significant against the activity of free t-PA.

Figure 7. (A) Cell viability of t-PA complexes with gelatin ($M_w = 100,000$) and zinc ions. (B) Cell viability of zinc ions. (C) Cell viability of 500 $\mu\text{g/ml}$ of gelatin ($M_w = 100,000$) and 50 $\mu\text{g/ml}$ of t-PA. The percentage of cell viability was expressed as 100% for non-treated cells. *, $P < 0.05$; significant against the viability of non-treated cells. The dotted line indicates 100% of cell viability.

Figure 8. Time profiles of body distribution of t-PA complexes with gelatin ($M_w = 100,000$, 10 mg/ml) and zinc ions (5 mM) or free t-PA after intravenous administration. After the intravenous administration of ^{125}I -labeled t-PA at different forms to mice, the radioactivity remaining was measured to evaluate their body distribution. (A) Retention in the blood circulation: (○) t-PA complexes with gelatin and zinc ions and (●) free t-PA. *, $P < 0.05$; significant against the radioactivity remaining of free t-PA at the corresponding time. (B) Tissue distribution; t-PA complexes with gelatin and zinc ions (white column) and free t-PA (black column).

Fig. 1 Uesugi *et al.* ↑

Fig. 2 Uesugi *et al.* ↑

Fig. 3 Uesugi *et al.* ↑

Fig. 4 Uesugi *et al.* ↑

Fig. 5 Uesugi *et al.* ↑

Fig. 6 Uesugi *et al.* ↑

Fig. 7 Uesugi *et al.* ↑

Fig. 8 Uesugi *et al.* ↑